marked.bio

PI3K inhibitor · small molecule

copanlisib

3 active trials across 4 of our biomarkers, targeting PI3K. Not approved for any biomarker on marked.bio yet.

Also known as BAY 80-6946, Aliqopa.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
PIK3CA activating mutation 2 6 Phase 2
MSI-H / dMMR 1 1 Phase 2
BRAF V600E 0 1 –
BRCA1/2 mutation 0 2 –

Trials

3 of 10 trials shown

  1. Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2018Primary completion 2021-01 NCT05490771

    copanlisib

    Patients must have PIK3CA mutation as determined via the MATCH Master Protocol

    PIK3CA activating mutationAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma

  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2015Primary completion 2027-12 NCT02465060

    adavosertibafatinibbinimetinibcapivasertibcopanlisibcrizotinibdabrafenibDasatinibdefactiniberdafitinibfexagratinibipatasertib

    …candidate for Z1M based on local Clinical Laboratory Improvement Act (CLIA) assessment of mismatch repair deficiency (MMRd) by immunohistochemistry (IHC) or microsatellite instability (MSI) status by polyme…

    MSI-H / dMMRAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma

  3. Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

    Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2019Primary completion 2024-07 NCT03842228

    copanlisibdurvalumabolaparib

    or actionable mutations in the PTEN gene, or hotspot mutations in the PIK3CA gene (E542, E545 or H1047 are accepted).

    PIK3CA activating mutationAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm